Hyaluronidase Power Injection Market - Top Companies and Manufacturers

In the News

• Argenx SE, an international immunology organization that works to modify the lives of people with serious autoimmune diseases, reported affirmative topline information from the Phase 3 ADAPT-SC study testing subcutaneous (SC) efgartigimod (1000 mg efgartigimod-PH20) as a therapy for generalized myasthenia gravis (gMG). Argenx delivered a biologics approval application (BLA) to the US FDA.
• The Food and Drug Administration (FDA) released a letter sanctioning the emergency utilization of the Alinity m Resp-4-Plex for the coexisting qualitative detection and distinction of RNA from SARS-CoV-2, influenza A virus (flu A), influenza B virus (flu B), and/or Respiratory Syncytial Virus (RSV) in anterior nasal or nasopharyngeal swab specimens accumulated by a healthcare provider (HCP).